Defence

United Therapeutics Co. Earnings Per Share Estimates. Wedbush (NASDAQ:UTHR) down for FY 2025


United Therapeutics Co. (NASDAQ: UTHRGet a rating) – Research analysts at Wedbush lowered their FY2025 earnings per share estimates for United Therapeutics in a report issued on Tuesday, September 20th. Wedbush analyst A. Argirides now expects that the biotech company will post earnings of $18.88 per share for the year, down from their prior estimate of $19.52. Wedbush has an “Outperform” rating and a $263.00 target price on the stock. The consensus estimate for United Therapeutics’ current year earnings is $14.90 per share. Wedbush also issued estimates for United Therapeutics’ FY2026 earnings at $30.18 EPS.

United Therapeutics (NASDAQ: UTHRGet a rating) last published its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 EPS for the quarter, missing the consensus estimate of $4.10 by ($1.69). The firm had revenue of $466.90 million for the quarter, compared to analyst expectations of $461.06 million. United Therapeutics had a net margin of 35.27% and a return on equity of 15.50%. United Therapeutics’s revenue for the quarter was up 4.6% on a year-over-year basis. In the same quarter last year, earnings per share amounted to $3.65.

A number of other equities analysts have also weighed in on the stock. Bank of America restated an “underperform” rating on shares of United Therapeutics in a research report on Tuesday. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Moderate Buy” and an average target price of $250.14, according to MarketBeat.

United Therapeutics stock rose 1.2%

shares of UTHR opened at $207.98 on Thursday. United Therapeutics has a fifty-two week low of $158.38 and a fifty-two week high of $245.48. The stock has a fifty-day moving average of $222.58 and a 200-day moving average of $209.33. The company has a market cap of $9.47 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 4.07 and a beta of 0.54. The company has a debt-to-equity ratio of 0.19, a gearing ratio of 7.83, and a current ratio of 8.10.

Hedge funds weigh in on United Therapeutics

A number of large investors have recently modified their holdings of the company. BlackRock Inc. increased its position in United Therapeutics by 0.9% during the first quarter. Now BlackRock Inc. now owns 4,277,089 shares of the biotechnology company’s stock valued at $767,350,000 after acquiring an additional 37,914 shares in the last quarter. Renaissance Technologies LLC raised its stake in United Therapeutics by 1.0% in the second quarter. Renaissance Technologies LLC now owns 2,793,591 shares of the biotechnology company’s stock valued at $658,282,000 after buying an additional 28,378 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after buying an additional 710,668 shares during the period. State Street Corp raised its stake in shares of United Therapeutics by 7.2% in the first quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock valued at $291,809,000 after acquiring an additional 109,226 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in United Therapeutics by 9.0% during the 4th quarter. Geode Capital Management LLC now owns 760,948 shares of the biotechnology company’s stock valued at $164,425,000 after purchasing an additional 62,882 shares during the period. 95.57% of shares are owned by hedge funds and other institutional investors.

Insider trading

In related news, the director Christopher Causey sold 3,500 shares of United Therapeutics stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $224.96, for a total transaction amounting to $787,360.00. Following the completion of the sale, the director now owns 2,835 shares in the company, valued at $637,761.60. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available through this link. In related news, EVP Paul A. Mahon sold 4,552 shares of the company’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $225.81 for a total value of $1,027,887.12. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares in the company, valued at $8,218,806.57. The sale was disclosed in a filing with the Securities and Exchange Commission, which can be accessed via this hyperlink. Also the director Christopher Causey sold 3,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $224.96, for a total amount of $787,360.00. Following the sale, the director now owns 2,835 shares in the company, valued at approximately $637,761.60. Disclosures for this sale can be found here here. Insiders have sold 27,212 shares of company stock worth $6,330,244 over the last three months. Corporate insiders own 12.40% of the company’s shares.

United Therapeutics Company Profile

(Get a rating)

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and abroad. Its commercial therapies include remodulin for the treatment of patients with pulmonary arterial hypertension (PAH) to reduce exercise-related symptoms; Tyvaso, an inhaled formulation of the prostacyclin analog treprostinil for the enhancement of exercise capacity in patients with PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet formulation of treprostinil for improving physical performance in patients with PAH; Unituxin, a monoclonal antibody for the treatment of high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to improve exercise capacity in patients with PAH.

See also

United Therapeutics (NASDAQ:UTHR) Earnings History and Valuation



Get news and ratings for United Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for United Therapeutics and related companies. MarketBeat.com’s FREE Daily E-Newsletter.

https://www.defenseworld.net/2022/09/23/fy2025-eps-estimates-for-united-therapeutics-co-decreased-by-wedbush-nasdaquthr.html United Therapeutics Co. Earnings Per Share Estimates. Wedbush (NASDAQ:UTHR) down for FY 2025

Back to top button